{
  "pmcid": "10638529",
  "sha256": "cefe22c35c32ea7a5e0487cf0ce9914d26dbfec5ec2a36782eb3d8523ec06561",
  "timestamp_utc": "2025-11-09T15:10:21.256177+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.4965306122449,
    "reading_ease": 51.91275510204082,
    "word_count": 294
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This parallel multicentre RCT investigated the use of Fluobeam ® LX to visualize the parathyroid glands by autofluorescence during total thyroidectomy compared with no use."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients were randomized 1 : 1 and were blinded to the group allocation."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "investigated the use of Fluobeam ® LX to visualize the parathyroid glands by autofluorescence during total thyroidectomy compared with no use."
      },
      "Objective": {
        "score": 1,
        "evidence": "The hypothesis was that autofluorescence enables identification and protection of the parathyroid glands during thyroidectomy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was the rate of low parathyroid hormone (PTH) levels the day after surgery."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Patients were randomized 1 : 1 and were blinded to the group allocation."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Patients were randomized 1 : 1 and were blinded to the group allocation."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Some 535 patients were randomized"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "486 patients received an intervention according to the study protocol, 246 in the Fluobeam ® LX group and 240 in the control group."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "64 patients (26.0 per cent) in the Fluobeam ® LX group and 77 (32.1 per cent) in the control group had low levels of PTH after thyroidectomy ( P = 0.141; relative risk (RR) 0.81, 95 per cent c.i. 0.61 to 1.07)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No specific harm related to the use of Fluobeam ® LX was reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Registration number: NCT04509011 ( http://www.clinicaltrials.gov )."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}